Table 2.
Summary and analysis of rescue medication use
| Rescue use, puffs/day, weeks 1–24 | UMEC/VI | TIO |
|---|---|---|
| ITT population, n | 776 | 764 |
| LS mean change from baseline (SE) | −2.0 (0.09) | −1.40 (0.10) |
| UMEC/VI vs. TIO, OR (95% CI) | −0.5 (−0.8 to −0.3)* | |
| MN population, n | 241 | 225 |
| LS mean change from baseline (SE) | −1.6 (0.18) | −1.1 (0.18) |
| UMEC/VI vs. TIO, OR (95% CI) | −0.5 (−0.9 to 0.0)‡ | |
| Rescue-free episodes | ||
| ITT population, n ‡ | 776 | 764 |
| Patients achieving increasea, n(%) | 357 (46) | 273 (36) |
| UMEC/VI vs. TIO, OR (95% CI) | 1.5 (1.2 to 1.9)* | |
| MN population, n ‡ | 241 | 225 |
| Patients achieving increase, n(%) | 114 (47) | 84 (37) |
| UMEC/VI vs. TIO, OR (95% CI) | 1.5 (1.0 to 2.2)§ | |
CI confidence interval, ITT intent to treat, LS least squares, MN maintenance-naïve, OR odds ratio, TIO tiotropium, UMEC umeclidinium, VI vilanterol
* P < 0.001, † P < 0.01; § P < 0.05, ‡ P = 0.066 for UMEC/VI vs. TIO
‡ n is the number of patients with analyzable data at the current time point
aPatients demonstrating a treatment effect similar to 1 extra rescue-free month per year or 2 extra rescue-free weeks in 24 (a change from baseline ≥8.3% over weeks 1–24)